CELGENE THALIDOMIDE WOULD BE DISTRIBUTED ONLY TO REGISTERED PHARMACIES; REGISTRY WOULD TRACK INDICATION OF EACH Rx; FDA COMMITTEE SUPPORTS LEPROSY USE
Celgene's proposal for thalidomide distribution would register only a small number of pharmacies that could purchase and dispense the drug. "We do not expect that a high proportion of pharmacies in the U.S. today will be involved," Celgene's Brian Williams told FDA's Dermatologic & Ophthalmic Drugs Advisory Committee meeting Sept. 4.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth